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Summary
Objective: To determine the frequency and length of treatment interruptions among new
pulmonary tuberculosis (TB) patients and to evaluate the duration of interruption associated
with default in the tuberculosis services of six Russian regions.
Methods: This was a retrospective study of all adult patients with new pulmonary TB enrolled for
treatment from April 1 to September 30, 2003. Data from patients with treatment outcomes of
default (n = 84), failure (n = 130), death (n = 113), and success (n = 1444) were analyzed.
Results: The default rate was 4.6%. Treatment interruptions were frequent: 63% of patients who
defaulted and 36% of those successfully treated had interruptions of treatment during the
intensive phase, and 30% of those who defaulted and 45% of those with a successful outcome
had interrupted treatment during the continuation phase. The length of treatment interruptions
was 1—125 days during the intensive phase and 1—127 days during the continuation phase among
patients with outcomes other than default. Patients with treatment gaps of 2—8 weeks during the
intensive phase included 15.5% of defaulters, 13.9% of those with an outcome of failure, and 4.4%
of those with treatment success. The integrated probability of default was50% in those patients
whomissed at least 2—3 consecutive days of treatment during the intensive phase and at least one
day during the continuation phase.
Conclusion: Treatment interruptions were frequent in TB patients in the six Russian regions.
Interventions to improve treatment adherence in patients are necessary. Social support and
incentive programs should be universally available for all patients from the start of the
continuation phase of treatment, during the intensive phase for patients considered to be at
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risk for default, and for those patients who have missed at least 2—3 days of treatment during the
intensive phase. Directly observed therapy (DOT) at home could be a recommendation for some
patients.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculosis (TB) has emerged as a serious public health
problem in the Russian Federation since the dissolution of
the Soviet Union in 1991.1 The Russian Federation ranks
twelfth among the 22 countries with the highest TB burden
as defined by the World Health Organization (WHO).2 In 2003,
a study on a cohort of TB patients treated under the directly
observed therapy short-course (DOTS) strategy in Russia
showed only 61% of patients had a successful treatment
outcome, while 7.8% of patients defaulted treatment, 12%
had treatment failure, and 10% died.2 These relatively poor
results are primarily linked to the high prevalence of drug
resistance, including multidrug-resistant (MDR)-TB.2 Offi-
cially reported mean rates of MDR-TB for Russia range from
7.8—8.1% in new cases to 14.5—16.5% in previously treated
cases;3 however, MDR-TB rates in several settings are
reported to be as high as 23% in new cases and 60% in
previously treated cases.4—6 The development of drug resis-
tance is mainly attributed to: incomplete or inadequate
treatment of patients with TB through weaknesses in TB
control programs, inappropriate prescribing by providers,
interruption of drug supply, failure to support patients on
treatment, lack of infection control precautions, and poor
compliance with treatment.6,7
Poor compliance to treatment is considered one of the
most serious problems of TB control in the Russian Federa-
tion. The reported default rate in WHO-supported Russian
regions, where case management is widely used (which
includes DOT, coordination of ongoing care and services
between inpatient and outpatient TB care providers, other
clinical care providers, and social workers, referrals for
psycho-social needs, patient education, and incentives for
patients), is 3—20%, whilst in other regions, default rates may
reach 30%.3,8 Patients who default treatment are at
increased risk for the development of drug resistance and
relapse.7 In addition to relatively high default rates in Russia,
frequent shorter treatment interruptions have also been
reported. For example, in 1999 in Ivanovo oblast, treatment
interruptions lasting less than 2 months (2—8 weeks)
occurred in 28% of smear-positive patients.9 Shorter inter-
ruptions of treatment are also a point of concern, as non-
compliance with treatment may lead to persistence and
resurgence of TB, prolonged infectiousness, and increased
transmission rates.10,11 Non-adherent patients require longer
periods of treatment and are less likely to complete treat-
ment compared to patients who are compliant.10,12
This study was therefore designed to determine the fre-
quency and length of treatment interruptions among new
patients with pulmonary TB in Russia, and to evaluate the
duration of treatment interruptions associated with the out-
come of default. We aimed to develop practical recommen-
dations on when it is necessary to start interventions for all
patients identified as belonging to risk groups, in order to
prevent default.Methods
Study population
The study population included all patients with new pulmon-
ary TB aged 16 years, who were enrolled for treatment on
the Tuberculosis Register13 from April 1 to September 30,
2003 in six Russian regions (Ivanovo, Orel, Vladimir, Belgorod,
and Pskov oblasts, and the Republic of Chuvashia) (Table 1).
All study regions are supported by the WHO and partners
(International Federation of Red Cross and Red Crescent
Societies and the US Centers for Disease Control and Preven-
tion). The DOTS strategy of TB control was implemented in
Ivanovo region beginning in 1995, in Orel in 1999, in Vladimir
in 2000, and in the three other regions beginning in 2002.
Social support programs for patients were in place in all six
regions beginning in 1999—2003.8 TB diagnosis was based on a
bacteriologic confirmation by smear or culture. A clinical TB
diagnosis was based on chest radiographic findings and clin-
ical signs.14 According to traditional Russian standards of
care, the majority of patients received treatment in hospital
during the intensive phase, while during the continuation
phase the majority of patients were treated on an ambula-
tory basis under DOT on a daily basis or intermittently (3
times a week); however, for patients in our study this infor-
mation was not collected. The WHO TB Control Programme in
Russia determined the project to be a retrospective observa-
tional study, therefore ethical approval and informed con-
sent from patients were not required.
Data collection and definitions
A standardized questionnaire was designed for data collec-
tion. Demographics, social history information, and micro-
biological laboratory results were abstracted from patient
medical records. Information on treatment outcomes was
obtained from the TB register.13 Transferred patients were
excluded from the study as information on treatment out-
come was not available.
The frequencies and lengths of treatment interruptions
during both phases of treatment were obtained from the ‘TB
treatment card’.13 For each enrolled patient with a TB
treatment card, we counted the total number of days of
non-consecutive interruption (i.e., for how many days in
total did the patient not receive TB medications during each
phase of treatment), the maximum number of consecutive
days of treatment interruption (i.e., the longest period
during each phase of treatment when the patient did not
receive TB medications; for defaulters this was the longest
period of consecutive interruption before an interruption of
8 consecutive weeks), and the total number of interrup-
tions (i.e., number of periods when the patient did not
receive TB medications during each phase of treatment with
the shortest possible period of not taking drugs equal to one
day).
Table 1 Epidemiology of TB in the adult civilian population in six Russian regions, 2003a.
Region Total population
of the region
Absolute number
of registered new
pulmonary TB cases
TB notification
rate (number of
new cases/100 000)
TB prevalence (number
of cases/100 000)
TB mortality rate
(number of TB
deaths/100 000)
Orel 850 000 502 60.9 207.6 6.7
Ivanovo 1 129 800 695 64.0 188.9 18.8
Vladimir 1 503 700 1207 81.6 214.1 20.6
Chuvashia 1 305 000 926 72.9 262.4 15.6
Pskov 747 600 595 81.3 173.9 31.9
Belgorod 1 513 100 984 82.2 135.6 8.9
a Source: Analytical review of the situation with tuberculosis in the Russian Federation, 2004: characteristics of epidemiological process
and TB services. Moscow, Russia: Ministry of Health and Social Development of the Russian Federation, Central Research Institute of Public
Health and IT, and Research Institute of Phthisiopulmonology of the Sechenov Moscow Medical Academy; 2006 (in Russian).
364 W. Jakubowiak et al.The standard WHO definitions of patient categories and
treatment outcomes were used.14,15 The outcome of treat-
ment default was defined as interruption of treatment for
eight consecutive weeks or more.14,15 Treatment interrup-
tion was defined as any interruption of treatment for at least
one day, but for <8 consecutive weeks. A treatment gap was
defined as a treatment interruption lasting 2 consecutive
weeks and <8 consecutive weeks.9
Data analysis
Data were entered into a database using Microsoft Excel
2000 software (Microsoft Corp., Redmond, WA, USA). SAS
software, version 9.1 (SAS Institute Inc., Cary, NC, USA) was
used for statistical analysis. Patient individual level data
were analyzed. For continuous data, the two-sample t-test
was used for normally distributed variables; otherwise the
Wilcoxon non-parametric test was used. TheMantel—Haens-
zel Chi-square test was used to test for differences in
proportions for categorical data; when the expected value
of a cell was <5, Fisher’s exact test was used instead. The
Mantel—Haenszel odds ratio (OR) and corresponding 95%
confidence interval (CI) was calculated for dichotomous
variables. A p-value of 0.05 was defined as statistically
significant.
The integrated probability of default was calculated by
dividing the summary number of patients who defaulted
treatment by each day of treatment, by the total number
of patients who defaulted treatment (N = 84). Then inte-
grated probability of default was calculated for the number
of days of non-consecutive interruption and for the maximum
number of consecutive days of treatment interruption (for
the intensive and continuation phases of treatment). We
found and reported cut-off points in the number of days of
interruption (non-consecutive and maximum number of con-
secutive days) corresponding to 50% and 75% integrated
probability of default.
Results
During the study period a total of 1805 pulmonary TB patients
from the six regions were enrolled. The mean age of patients
was 43 years (range 16—86); the majority (73%) were male.
Fifty-seven percent of patients lived in a city, and 32% lived a
distance of 5 km from their treatment site. Overall, 37% of
patients were unemployed, 24% abused alcohol, 13% had ahistory of imprisonment, and 3% were homeless. Forty-six
percent of patients were smear-positive. The treatment
outcomes in the six regions were as follows: 1444 (80%)
patients had successful or completed treatment, 84 (4.6%)
patients defaulted, 130 (7.2%) patients had treatment fail-
ure, 113 (6.3%) died, and 34 (1.9%) were transferred. The
default rate during the study period in the enrolled cohort of
patients (N = 1805) was 2.3% (n = 5) in Orel, 2.8% (n = 6) in
Ivanovo, 4.5% (n = 17) in Belgorod, 5.2% (n = 20) in Vladimir,
5.5% (n = 15) in Pskov, and 6.3% (n = 21) in Chuvashia. Among
patients who defaulted treatment, default occurred during
the intensive phase of treatment for 44% (37/84) of patients
and during the continuation phase for 56% (47/84) of
patients.
The frequency and length of treatment interruptions
among pulmonary smear-positive and smear-negative TB
patients are reported in Table 2. With regards to the subset
of smear-positive patients (N = 834), defaulted patients had
a significantly higher mean total number of days of non-
consecutive interruptions during the intensive phase com-
pared to patients with a successful treatment outcome (11.5
vs. 5.1 days), higher mean total number of interruptions (2.8
vs. 1.3), and longer mean maximum number of consecutive
days of treatment interruption (6.9 vs. 2.7 days). Smear-
positive patients who failed treatment had a significantly
higher mean total number of days of non-consecutive inter-
ruptions during the intensive phase compared to patients
with a successful treatment outcome (9.9 vs. 5.1 days),
higher mean total number of interruptions (2.1 vs. 1.3),
and longer mean maximum number of consecutive days of
treatment interruption (5.0 vs. 2.7 days). No significant
differences in frequency and length of treatment interrup-
tions were found with regards to the continuation phase for
smear-positive patients.
The association of treatment gaps (interruptions of 2—8
weeks) and default among pulmonary smear-positive and
smear-negative TB patients for both phases of treatment is
reported in Table 3. Similar results were obtained for the
subset of smear-positive patients with default and with out-
come of failure (data not shown).
The odds of treatment default among pulmonary smear-
positive and smear-negative TB patients increased from 2.1 in
patients who missed a total of 1—7 non-consecutive days of
treatment during the intensive phase to 4.6 in patients who
missed a total of>14 days of treatment (referent category ‘no
treatment interruptions’) (Table 4). During the continuation
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Treatment interruptions in new TB patients, Russia 365phase no positive associationwas found between total number
of days of non-consecutive interruptions anddefault;missing a
total of 1—7or 8—14 non-consecutive days of treatment during
the continuation phase was significantly less likely to have
occurred among defaulters compared to those with a success-
ful outcome (Table 4). Similar results were obtained for the
analysis of the association of default with the maximum
number of consecutive days of treatment interruption among
pulmonary smear-positive and smear-negative TB patients
(Table 5). A significant trend of increasing probability of
default was found with an increasing total number of days
of non-consecutive interruptions or maximum number of con-
secutive days of interruption during the intensive phase (both
p < 0.001), while no significant trend was found for interrup-
tions during the continuation phase (p = 0.21 and p = 0.05,
respectively) (Tables 4 and 5).
The integrated probability of default based on the number
of missed days of treatment is shown in Table 6.
Discussion
We found a relatively low default rate of 4.6% in the six
Russian regions (compared to up to 30% in other regions
according to the Russian Ministry of Health reports).3,8 How-
ever, treatment interruptions were common: 63% of
defaulted and 36% of successfully treated patients had inter-
ruptions of treatment during the intensive phase, and 30% of
defaulted and 45% of patients with successful treatment
outcomes had interrupted treatment during the continuation
phase. The length of treatment interruptions was 1—125 days
during the intensive phase and 1—127 days during the con-
tinuation phase without registering a default outcome, since
these treatment interruptions occurred in a non-consecutive
fashion (treatment was not interrupted for eight consecutive
weeks or more), and accordingly to standard WHO defini-
tions15 and the Russian Order14 such patients cannot be
registered as having a default outcome. The integrated
probability of default was50% in those patients who missed
at least 2—3 consecutive days of treatment during the inten-
sive phase, and at least one day of treatment during the
continuation phase.
A higher proportion of patients defaulted during the
continuation phase than during the intensive phase of
treatment. Historically the Russian TB control system
has anticipated lengthy and frequent hospitalizations for
TB patients.16,17 Current regulations do not have specific
standards or criteria for hospitalizations.14 At present the
mean duration of hospital stay in Russia is 86—90 days per
admission following the traditional approach to treating TB
patients in the hospital.18 In the six DOTS regions where
the study was conducted, the majority of patients received
treatment in the hospital during the intensive phase, while
the majority were treated as outpatients at TB services
during the continuation phase; thus, direct observation of
treatment was more easily ensured when a patient was
hospitalized. This may explain our findings of strong asso-
ciations of treatment default with higher total number of
days of non-consecutive interruptions, higher total number
of interruptions, and longer maximum number of consecu-
tive days of interruption during the intensive phase, while
any interruptions during the continuation phase were
not predictive of default. Similar to our findings, Santha
Table 4 Odds of treatment default for TB patients based on the number of total days of non-consecutive treatment interruptions
among pulmonary smear-positive and smear-negative TB patients (N = 1528).
Total days of non-consecutive interruptions Default
(n = 84) n (%)
Success
(n = 1444) n (%)
OR (95% CI) p-Value
Interruptions during the intensive phasea
0 31 (36.9) 928 (64.3) 1.0
1—7 21 (25) 301 (20.8) 2.1 (1.2—3.7) 0.01
8—14 14 (16.7) 98 (6.8) 4.3 (2.2—8.3) <0.001
>14 18 (21.4) 117 (8.1) 4.6 (2.5—8.5) <0.001
Interruptions during the continuation phaseb
0 59 (70.2) 793 (54.9) 1.0
1—7 9 (10.7) 251 (17.4) 0.5 (0.2—1.0) 0.04
8—14 3 (3.6) 130 (9.0) 0.3 (0.1—1.0) 0.04c
>14 13 (15.5) 270 (18.7) 0.7 (0.4—1.2) 0.16
a Cochran—Armitage trend test, two-sided, p < 0.001.
b Cochran—Armitage trend test, two-sided, p = 0.21.
c Fisher’s exact test.
Table 3 Treatment gaps (interruptions of 2—8 weeks) among pulmonary smear-positive and smear-negative TB patients with
treatment outcomes of success, default, and failure (N = 1658).
Treatment interruptions
for a consecutive 2—8 weeks
Success
(n = 1444)
Default (n = 84) Failure (n = 130)
n (%) n (%) OR (95% CI) a p-Valuea n (%) OR (95% CI) a p-Valuea
During intensive phase 63 (4.4) 13 (15.5) 4.0 (2.1—7.6) <0.001 18 (13.9) 3.5 (2.0—6.3) <0.001
During continuation phase 119 (8.2) 5 (6.0) 0.7 (0.3—1.8) 0.68b 13 (10) 1.2 (0.7—2.3) 0.49
During both phases 11 (0.8) 0 (0) - 1.00b 6 (4.6) 6.3 (2.3—17.3) <0.001
a OR and p-values for comparison to patients with success as the treatment outcome.
b Fisher’s exact test.
366 W. Jakubowiak et al.et al.19 found that a higher likelihood of default was
associated with irregularity in treatment during the inten-
sive phase. In a study by Chang et al.,20 poor, fair, or
unknown initial adherence (i.e., adherence during theTable 5 Odds of treatment default for TB patients based on max
among pulmonary smear-positive and smear-negative TB patients
Maximum number of consecutive days of interruption Defaul
(n = 84
Interruptions during intensive phasea
0 31 (36
1—7 35 (41
8—14 5 (6.0
>14 13 (15
Interruptions during continuation phaseb,d
0 58 (69
1—7 14 (16
8—14 7 (8.4
>14 4 (4.8
a Cochran-Armitage trend test, two-sided, p < 0.001.
b Cochran-Armitage trend test, two-sided, p = 0.05.
c Fisher’s exact test.
d Data were available for 83 defaulted patients, and 1436 patients wintensive phase) was found to be significantly associated
with treatment default.
Treatment interruption did not contribute to an outcome
of death, since patients who died had significantly shorterimum number of consecutive days of treatment interruptions
(N = 1525).
t
) n (%)
Success
(n = 1441) n (%)
OR (95% CI) p-Value
.9) 930 (64.5) 1.0
.7) 394 (41.7) 2.7 (1.6—4.4) <0.001
) 59 (4.1) 2.5 (0.9—6.8) 0.07c
.4) 58 (4.0) 6.7 (3.3—13.5) <0.001
.9) 793 (55.2) 1.0
.9) 418 (29.1) 0.5 (0.3—0.8) 0.009
) 113 (7.9) 0.9 (0.4—1.9) 0.69
) 112 (7.8) 0.5 (0.2—1.4) 0.22c
ith successful treatment.
Table 6 Integrated probability of default based on days of treatment interruptions among pulmonary smear-positive and smear-
negative TB patients with default outcome (N = 84).
Integrated probability
of default
Intensive phase Continuation phase
Total number of
days of non-consecutive
interruption
Maximum number
of consecutive days
of treatment interruption
Total number of days
of non-consecutive
interruption
Maximum number
of consecutive days
of treatment interruption
50% 3 2 1 1
75% 11 6 3 2
Treatment interruptions in new TB patients, Russia 367and fewer interruptions during both the intensive and
continuation phases compared to patients with a successful
outcome. Previous studies from two Russian regions have
found the survival time after TB diagnosis to be short (35—
40 days) in those who die.21,22 Major risk factors for an
outcome of death in Russia include markers of advanced TB
disease as a result of delayed diagnosis.21,22 Therefore,
factors other than treatment interruptions are likely to
be associated with increased TB mortality in Russia. Find-
ings in other studies have been controversial: several stu-
dies have demonstrated that death as an outcome is not
associated with non-compliance10 and irregular treat-
ment,19 while a study conducted in India showed that
irregular or inadequate chemotherapy resulted in a four-
fold increase in mortality.23
Based on our study results, the following practical
recommendations can be made. When a patient interrupts
treatment for a total of three or more non-consecutive
days, or two or more consecutive days during the intensive
phase, healthcare workers should promptly intervene and
all measures should be taken to secure compliance, since
the probability of default increases proportionally with an
increasing number of days of interruption. These patients
should be traced by telephone call or visit to their homes
to identify reasons for non-adherence. Interventions for
improving adherence should include: identification of
patients who are at high risk for default at the very
beginning of treatment, psychological counseling of
patients and health education, social support, and incen-
tives to keep patients on treatment. Social support and
incentive programs should be universally available for all
patients starting from the first day of the continuation
phase of treatment. DOT at home could be a recommenda-
tion for some patients.
Conclusions
In summary, treatment interruptions were common in TB
patients in six Russian regions, and treatment interruptions
could be lengthy even in patients without an outcome
of default. Social support and incentive programs
should be universally available for all patients from the
start of the continuation phase of treatment, during the
intensive phase for patients considered to be at risk for
default (such as the unemployed, alcohol abusers, and
the homeless),6 and for those patients who have missed
at least 2—3 days of treatment during the intensive phase.
All measures should be undertaken to keep patients on
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